Long-term outcomes in patients with polyarticular juvenile idiopathic arthritis receiving adalimumab with or without methotrexate. Issue 2 (13th July 2020)

• Record Type: Journal Article
• Authors: Lovell, Daniel J; Brunner, Hermine I; Reiff, Andreas O; Jung, Lawrence; Jarosova, Katerina; Němcová, Dana; Mouy, Richard; Sandborg, Christy; Bohnsack, John F; Elewaut, Dirk; Gabriel, Christos; Higgins, Gloria; Kone-Paut, Isabelle; Jones, Olcay Y; Vargová, Veronika; Chalom, Elizabeth; Wouters, Carine; Lagunes, Ivan; Song, Yanna; Martini, Alberto; Ruperto, Nicolino
• Is Part Of: RMD open. Volume 6:Issue 2(2020)
• Publication Date: 2020-07-13
• Subjects: Juvenile Idiopathic Arthritis -- Anti-TNF -- Adult Onset Still's Disease -- Methotrexate -- Arthritis -- Dermatomyositis -- Lupus Erythematosus -- Systemic -- Familial Mediterranean Fever -- Autoimmune Diseases; Musculoskeletal system -- Diseases -- Periodicals; Rheumatism -- Periodicals; 616.7005
• DOI: 10.1136/rmdopen-2020-001208
• Languages: English
• ISSNs: 2056-5933

Abstract

Abstract : Objectives: Long-term safety and efficacy of adalimumab among patients with juvenile idiopathic arthritis (JIA) was evaluated through 6 years of treatment. Methods: Children aged 4–17 years with polyarticular JIA were enrolled in a phase III, randomised-withdrawal, double-blind, placebo-controlled trial consisting of a 16-week open-label lead-in period, 32-week randomised double-blind period and 360-week long-term extension. Patients were stratified by baseline methotrexate use. Adverse events (AEs) were monitored, and efficacy assessments included JIA American College of Rheumatology (JIA ACR) 30%, 50%, 70% or 90% responses and the proportions of patients achieving 27-joint Juvenile Arthritis Disease Activity Score (JADAS27) low disease activity (LDA, ≤3.8) and inactive disease (ID, ≤1). Results: Of 171 patients enrolled, 62 (36%) completed the long-term extension. Twelve serious infections in 11 patients were reported through 592.8 patient-years of exposure. No cases of congestive heart failure-related AEs, demyelinating disease, lupus-like syndrome, malignancies, tuberculosis or deaths were reported. JIA ACR 30/50/70/90 responses and JADAS27 LDA were achieved in 66% to 96% of patients at week 104, and 63 (37%) patients achieved clinical remission (JADAS27 ID sustained for ≥6 continuous months) during the study. Attainment of JIA ACR 50 or higher and JADAS27 LDA or ID in the initial weeks were the best predictors of clinical remission. Mean JADAS27 decreased from baseline, 22.5 (n=170), to 2.5 (n=30) at week 312 (observed analysis). Conclusions: Through 6 years of exposure, adalimumab was well tolerated with significant clinical response (up to clinical remission) and a relatively low retention rate.